COVID-19, caused by the SARS-CoV-2 virus, can lead to severe immune responses and complications like acute lung injury and organ failure, especially in patients with pre-existing immune disorders.
A case study highlights a young female with severe Crohn's disease who successfully battled COVID-19 pneumonia while continuing treatment with adalimumab and prednisone, which control her Crohn's symptoms.
This case suggests that TNF-α inhibitors like adalimumab may help mitigate severe COVID-19 complications by blocking the inflammatory processes associated with the disease, in addition to the effects of prednisone.